State of Michigan Retirement System Sells 200 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

State of Michigan Retirement System cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,830 shares of the medical research company’s stock after selling 200 shares during the period. State of Michigan Retirement System’s holdings in Charles River Laboratories International were worth $2,553,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Wellington Management Group LLP boosted its holdings in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares during the period. State Street Corp boosted its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after buying an additional 47,221 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Charles River Laboratories International by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after buying an additional 32,311 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares during the period. 98.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on CRL shares. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $198.36.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $176.20 on Friday. The stock has a market cap of $9.01 billion, a PE ratio of 1,174.68, a PEG ratio of 4.54 and a beta of 1.45. The company’s fifty day moving average is $169.35 and its 200 day moving average is $186.07. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm’s revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.46 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).